SAUDI ARABIA · KSA PARTNERSHIP
Partnership inSaudi Arabia.
For Saudi distributors, pharmacy groups, healthcare importers and commercialization partners: Continuum Innovative is a US hair-loss biology platform with peer-reviewed evidence, a six-program patent-pending portfolio, and products that have been carried in the Gulf for more than twenty-five years.
We are seeking one serious Saudi partner rather than several. Registration and market execution belong to that partner; the science, formulations and documentation come from us.
1
PREFERRED SAUDI PARTNER SOUGHT
25+
YEARS OF GCC COMMERCIAL RECORD
6
PATENT-PENDING IP PROGRAMS
2
BRANDS AVAILABLE FOR KSA
WHY SAUDI ARABIA MATTERS TO US
The largest single Gulf opportunity.
Saudi Arabia is the largest consumer market in the Gulf Cooperation Council and, for a hair-loss portfolio, the single most consequential territory in the region. Demand in this category is persistent, culturally salient and largely insensitive to economic cycles.
Continuum's products already have regional history: the platform's brands were carried for more than two decades across Gulf pharmacy networks including Boots Middle East, Aster Pharmacy, Life Pharmacy and Bin Sina Pharmacy. For a Saudi partner, that means the category question is settled and the conversation can move directly to registration, channel and volume.
What we are offering a Saudi partner
Distribution rights for HairGenesis® and TrichoCyte™ in the Kingdom, or a license to build inside the partner's own brand.
What we expect the partner to own
Saudi registration and regulatory filings, importation, pharmacy and clinic channel execution, and commercial accountability in-market.
What we contribute
Formulations, delivery technology, peer-reviewed evidence, mechanism and claim-substantiation documentation, technical files and direct scientific access to the founder.
What we do not represent
Continuum does not hold Saudi regulatory approvals and does not act as a Saudi registration agent or regulatory consultancy. We support the partner's own regulatory process with the scientific and technical materials within our competence.
THE SCIENTIFIC BASIS
Why this is not another imported hair supplement.
The portfolio rests on published mechanism work, not marketing language. Botanical 5α-reductase inhibition was tested in a randomized, double-blind, placebo-controlled trial published in the Journal of Alternative and Complementary Medicine in 2002. Anti-inflammatory gene-expression effects in keratinocytes were published in Evidence-Based Complementary and Alternative Medicine. Androgen-marker blockade was published in Phytotherapy Research. Delivery-enhanced botanical work was published in Cosmetics and, more recently, in the Journal of Complementary Research and Alternative Medicine.
For a Saudi partner facing pharmacist scrutiny and physician questions, that published record is the asset — it is what makes the claim set defensible rather than aspirational.
- Five peer-reviewed publications underpinning mechanism and delivery.
- TrichoCyte™ — botanical 5α-reductase inhibition with β-cyclodextrin delivery.
- HairGenesis® — nano-enabled oral plus topical system with GCC retail history.
- Twenty-five years of Gulf distribution through the region's leading pharmacy networks.
COMMON QUESTIONS FROM SAUDI PARTNERS
Answered directly.
Is Saudi exclusivity available?
Who registers the products with the Saudi authorities?
Are the products manufactured to US standards?
Can we sell under our own brand?
Is Arabic-language material available?
RELATED
NEXT STEP
One message from a Saudi partner is enough.
Tell us your channel in the Kingdom and what you currently distribute. We will send the scientific and commercial package and propose a structure.
OPEN A SAUDI DISCUSSION